Project Grant R01CA292532
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$540K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $684,367 to support research aimed at identifying intratumoral microbiome profiles and spatial immune signatures that can predict response to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer. The project, led by researchers at Baylor College of Medicine, will analyze pre-treatment tumor samples from three independent cohorts (totaling...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $636,222 to the University of Pittsburgh to conduct research on how immune checkpoint inhibitor-associated bacteria can modulate tumor immunity in cancer, with a focus on melanoma. The overarching goal is to understand the mechanisms by which certain gut bacteria can produce aryl hydrocarbon receptor (AhR) ligands that enhance anti-tumor CD8+ T cell (TC1) immunity, thereby...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395), will support research at the University of Chicago to investigate the use of genetically-engineered Bifidobacterium bacteria for enhancing tumor control in combination with radiotherapy and/or immunotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). The $581,087 award, with a period of performance from July 1, 2024 to June 30, 2029, will focus...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to modulate the human microbiome to enhance immune responses against cancer. The $179,988 award to The Leland Stanford Junior University, a private research university, aims to identify bacterial functions that can improve response to immune checkpoint blockade cancer therapies. Key objectives include: Aggregating and analyzing metagenomic data to identify microbial genes...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $281,606 to New York University School of Medicine to conduct research on harnessing gut-derived Bacteroides bacteria to drive systemic anti-tumor immunity for lung cancer. The research aims to elucidate the mechanisms by which particular gut commensals can elicit an immune response in distant tumors, including determining the anatomical site and immune cell types first triggered...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will support research at The Leland Stanford Junior University to elucidate how microbial microproteins modulate macrophage function, a critical component of the tumor immune response. The $640,522 award, commencing on May 1, 2025 and running through April 30, 2030, will fund a multi-pronged effort to: 1) determine the molecular mechanisms by which two specific microbial proteins regulate...
This $670,358 federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) supports research at the University of Texas MD Anderson Cancer Center to investigate the role of B cells in mediating response to neoadjuvant immune-based therapy for patients with resectable non-small cell lung cancer (NSCLC). The key objectives are to: 1) Determine the transcriptional, immunogenomic, and spatial landscapes of B lineage cells in NSCLC treated with...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center (MD Anderson) will fund research to define the landscape of bacterial-colonized microniches within tumors and their role in intratumoral heterogeneity. The total award of $626,893 will be provided over a 5-year period from September 1, 2024 to August 31, 2029. The key products or services to be delivered under this grant include:...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $351,131 to the University of Miami to support research aimed at overcoming chemotherapy and immunotherapy resistance in pancreatic cancer. The key objectives are to: Mechanistically dissect the signaling and spatial interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that drive treatment resistance in pancreatic ductal...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) will fund research to define novel mechanisms by which the gut microbiota (trillions of microbes in the intestine) influence anti-tumor immunity and the response to cancer immunotherapies. The $138,240 award to Weill Medical College of Cornell University will support studies to understand how host-microbiota interactions promote tumor growth by limiting metabolites that...